Presenter Abstract title Day
Christian Poulie Discovery of β-arrestin-2 biased agonists of the 5-HT2A receptor based on 25cn-nboh Thursday
Helena Aicher Modulation of self-referential information processing, mindfulness, compassion, and other psychotherapy-relevant change mechanisms through ayahuasca-analogues – first insights from an intervention study with healthy humans Thursday
Federico Cavanna Microdosing with psilocybin mushrooms: a double-blind placebo-controlled study Thursday
Mauro Cavarra Psychedelic-assisted psychotherapy – a systematic review of associated psychological interventions Thursday
Olga Chernoloz Randomized, double-blind, placebo-controlled study assessing the efficacy of microdosed psilocybin on reducing depression and/or anxiety levels in adults Thursday
James Close Co-design of a strategy for patient and public involvement in psychedelic research Thursday
Laura  de la Fuente Temporal irreversibility of neural dynamics as a signature of consciousness Thursday
Helle Kaasik Chemistry of ayahuasca and pharmahuasca: interlaboratory comparison Thursday
Maja Kohek Ayahuasca and public health: health status of people who regularly participate in ayahuasca ceremonies in spain and the netherlands Thursday
Eline Pottie In vitro functional characterization of psychedelic substances using different 5-HT2AR bioassays Thursday
Deborah Rudin Classic psychedelics differentially activate serotonin 2a receptor signaling pathways Thursday
Marcelo Falchi LSD, madness and healing: mystical experiences as possible link between psychosis model and therapy model Thursday
Federico Zamberlan Understanding the molecular mechanisms of functional selectivity in psychedelics: deep learning applied to the conformational change and transcriptome fingerprint analysis Thursday
James W. Sanders Micro-phenomenology of the intravenous DMT experience Thursday
Agnieszka Sekula Virtual reality as a moderator of psychedelic-assisted psychotherapy Thursday
Daniel Martins Kosmicare: experimenting the future harm reduction interventions Thursday
Eirini Argyri Psychedelic-induced psychological transformations: calling for balance in the novel narratives Friday
Julia Bornemann Co-development of the study protocol for “psilocybin in patients with fibromyalgia: EEG-measured brain biomarkers of action” Friday
James Curley A thematic examination of the spiritual usage of cannabis Friday
Hannah Douglass Study protocol and 8-month progress update: psilocybin as a treatment for anorexia nervosa: a pilot study Friday
Jerome Herpers A five-step model to explain the functional mechanisms of MDMA-assisted therapy for post-traumatic stress disorder Friday
Maggie Kiraga Psychedelic microdosers report therapeutic motivations and longitudinal improvements in mood, mental health and psychomotor functioning relative to non-microdosing comparators Friday
Vito Palmisano Photoswitchable psychedelics Friday
Joseph Peill Validation of the psychological insight scale: a new scale to assess psychological insight following a psychedelic experience Friday
Edriss Samani Development of LIWC dictionaries for netnographic studies on psychedelics Friday
Nige / Wai Fung Netzband / Tsang Amazonian ayahuasca and mental health outcomes in an adapted traditional setting – an overview Friday
Jan Thomann Development of a bioanalytical method for quantifying mescaline and its metabolites in human plasma and urine. Friday
Filip Tylš Integration of ketamine-assisted psychotherapy into mental health: pilot results Friday
Dóra Révész A longitudinal and transcultural assessment of the relationship between psychedelic drug use, psychological well-being, post-traumatic growth, and covid-19 pandemic stress Friday
Amir Lofti Antidepressant properties of 5-MeO-DMT: a behavioral and pharmacological investigation Friday
Villa / Jennifer Zaskia/ Montjoy Serial intramuscular ketamine-assisted psychotherapy efficacy in chronic posttraumatic-stress disorder Friday
Johannes Reckweg A phase 1, dose-ranging study to assess safety and psychoactive effects of a vaporized 5-methoxy-n,n-dimethyltryptamine formulation (gh001) in healthy volunteers Friday
Eline Haijen Microdosing with psychedelics to self-medicate for ADHD symptoms in adults: a prospective naturalistic study Saturday
Tommaso Barba Summer of love: effects of psychedelic drugs on sexual functioning in healthy and depressed subjects Saturday
Jon Sharp Analgesic potential of macro- and microdoses of classical psychedelics in chronic pain sufferers: a population survey Saturday
Natalie Ertl The effect of psilocybin therapy for depression on low-frequency brain activity in response to music Saturday
Laura Kärtner Psychedelic microdosing: more than “just” placebo? Saturday
Pablo Mallaroni The neurochemical substrates of psychedelic altered states of consciousness Saturday
Lea Mertens Efficacy and safety of psilocybin in treatment-resistant major depression (EPIsoDE) – rationale, study design and insights from individual cases Saturday
Mikael Palner Detailed neurobiological changes in the rat brain, mapped over one week following a single psychedelic dose of psilocybin Saturday
Carolina Seybert Psychotherapy approaches in psychedelic-assisted treatments: a systematic review Saturday
Stefano Johannes Maria van der Aalst Repeated intravenous esketamine treatment in patients with ECT-resistant major depression disorder Saturday
Henry Whitfield The spectrum of selves (SoS) model for psychedelic-assisted therapy: further developing the approach following a high-density longitudinal data study Saturday
Isabel Wiessner LSD, afterglow and hangover: increased episodic memory and verbal fluency, decreased cognitive flexibility Saturday
Aleksandra Wingert Examining the prevalence and impact of adverse life event re-experiencing during the ceremonial use of ayahuasca. Saturday
Rayyan Zafar Looking through the doors of perception: the past, present and future of psychedelics to treat addiction Saturday
Ksenia Cassidy Childhood trauma + ayahuasca = post-traumatic growth? Saturday
David Reydellet EEG connectivity during the DMT experience Saturday
Benjamin Mudge Including bipolar people in psychedelic research Saturday

Ready To Attend ICPR 2022?​

Join the leading conference in Europe dedicated to advancing psychedelic research and therapies.

Want The Latest Updates?

Subscribe below to ICPR Newsletter and get all the latest updates, including discount tickets!

By clicking subscribe, I confirm to receive emails from the OPEN Foundation and agree with its privacy & terms.